Stephen J Nicholls

Summary

Publications

  1. ncbi request reprint New Drugs for HDL-C Disorders: The Beginning
    MyNgan Duong
    South Australian Health and Medical Research Institute PO Box 11060 Adelaide, SA, 5001, Australia
    Curr Med Chem 21:2947-51. 2014
  2. ncbi request reprint Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia
    Curr Vasc Pharmacol 12:649-52. 2014
  3. ncbi request reprint Update in therapeutic approaches to plaque stabilization
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia
    Curr Atheroscler Rep 16:392. 2014
  4. doi request reprint Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, Adelaide, Australia
    JAMA 310:1135-44. 2013
  5. ncbi request reprint Imaging progression of coronary atherosclerosis
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, University of Adelaide, South Australia, Australia
    Circ J 77:3-10. 2013
  6. doi request reprint Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study
    Rishi Puri
    Discipline of Medicine, University of Adelaide, South Australia
    Circ Cardiovasc Imaging 6:674-82. 2013
  7. ncbi request reprint Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy
    Yu Kataoka
    Heart Health, South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia Electronic address
    Am J Cardiol 114:549-54. 2014
  8. doi request reprint Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
    Stephen J Nicholls
    South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia
    JAMA 311:252-62. 2014
  9. ncbi request reprint Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)
    Michael H Davidson
    From the Department of Medicine, University of Chicago, IL M H D Icahn School of Medicine at Mount Sinai, New York, NY R S R Biofortis Clinical Research, Addison, IL K C M Cardiology, University of Adelaide, Adelaide, Australia S J N Consultant Cardiologist, Royal Adelaide Hospital, Adelaide, Australia S J N Section of Cardiology, Section of Atherosclerosis and Vascular Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX C M B the Maria and Alando J Ballantyne, MD, Atherosclerosis Laboratory, and Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, TX C M B Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago T M and Global Pharmaceutical Research and Development D M C, L A W, M T K, H S C, J C S, and Data and Statistical Sciences A L, AbbVie Inc, North Chicago, IL
    Arterioscler Thromb Vasc Biol 34:1298-306. 2014
  10. doi request reprint C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy
    Rishi Puri
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH R P, S E N, K U, Y K, S J N Cardiovascular Division, Brigham and Women s Hospital, Boston, MA P L C5Research, Cleveland Clinic, Cleveland, OH M S Section of Cardiovascular Research, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX C M B Centre for Vascular Research, University of New South Wales, Sydney, Australia P J B INSERM Dyslipidaemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France M J C West German Heart Center, Essen, Germany R E AstraZeneca, Wilmington, DE J S R and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia S J N
    Circulation 128:2395-403. 2013

Collaborators

Detail Information

Publications14

  1. ncbi request reprint New Drugs for HDL-C Disorders: The Beginning
    MyNgan Duong
    South Australian Health and Medical Research Institute PO Box 11060 Adelaide, SA, 5001, Australia
    Curr Med Chem 21:2947-51. 2014
    ..A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed. ..
  2. ncbi request reprint Controversies on HDL: Should it be a Target Biomarker in Patients with Lipid Disorders?
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia
    Curr Vasc Pharmacol 12:649-52. 2014
    ..This review will reflect on challenges faced in developing new effective HDL targeted therapies. ..
  3. ncbi request reprint Update in therapeutic approaches to plaque stabilization
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia
    Curr Atheroscler Rep 16:392. 2014
    ..The approaches to management of plaque stabilization are reviewed. ..
  4. doi request reprint Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, Adelaide, Australia
    JAMA 310:1135-44. 2013
    ..Blood pressure reduction and renin-angiotensin-aldosterone system inhibition are targets for treatment of atherosclerosis. The effect of renin inhibition on coronary disease progression has not been investigated...
  5. ncbi request reprint Imaging progression of coronary atherosclerosis
    Stephen J Nicholls
    South Australian Health and Medical Research Institute, University of Adelaide, South Australia, Australia
    Circ J 77:3-10. 2013
    ..The findings of these studies, the clinical implications and ongoing advances will be reviewed...
  6. doi request reprint Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study
    Rishi Puri
    Discipline of Medicine, University of Adelaide, South Australia
    Circ Cardiovasc Imaging 6:674-82. 2013
    ..We aimed to investigate mechanistic relationships between atheroma volume and endothelial function in patients with non-ST-segment-elevation myocardial infarction (NSTEMI) using intravascular ultrasound...
  7. ncbi request reprint Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy
    Yu Kataoka
    Heart Health, South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia Electronic address
    Am J Cardiol 114:549-54. 2014
    ..This finding varies according to the size of plaque lipid content, being less effective in lipid-loaded plaques. ..
  8. doi request reprint Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial
    Stephen J Nicholls
    South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia
    JAMA 311:252-62. 2014
    ..The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown...
  9. ncbi request reprint Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)
    Michael H Davidson
    From the Department of Medicine, University of Chicago, IL M H D Icahn School of Medicine at Mount Sinai, New York, NY R S R Biofortis Clinical Research, Addison, IL K C M Cardiology, University of Adelaide, Adelaide, Australia S J N Consultant Cardiologist, Royal Adelaide Hospital, Adelaide, Australia S J N Section of Cardiology, Section of Atherosclerosis and Vascular Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX C M B the Maria and Alando J Ballantyne, MD, Atherosclerosis Laboratory, and Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, TX C M B Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago T M and Global Pharmaceutical Research and Development D M C, L A W, M T K, H S C, J C S, and Data and Statistical Sciences A L, AbbVie Inc, North Chicago, IL
    Arterioscler Thromb Vasc Biol 34:1298-306. 2014
    ....
  10. doi request reprint C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy
    Rishi Puri
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH R P, S E N, K U, Y K, S J N Cardiovascular Division, Brigham and Women s Hospital, Boston, MA P L C5Research, Cleveland Clinic, Cleveland, OH M S Section of Cardiovascular Research, Baylor College of Medicine, and the Methodist DeBakey Heart and Vascular Center, Houston, TX C M B Centre for Vascular Research, University of New South Wales, Sydney, Australia P J B INSERM Dyslipidaemia and Atherosclerosis Research Unit, Hopital de la Pitie, Paris, France M J C West German Heart Center, Essen, Germany R E AstraZeneca, Wilmington, DE J S R and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia S J N
    Circulation 128:2395-403. 2013
    ..The association between changes in CRP levels with plaque progression and MACE in the setting of maximally intensive statin therapy is unknown...
  11. doi request reprint Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy
    Yu Kataoka
    South Australian Health and Medical Research Institute, Level 9, 121 King William Street, Adelaide, SA, 5000, Australia
    Future Cardiol 9:177-86. 2013
    ....
  12. ncbi request reprint Lipid pharmacotherapy for treatment of atherosclerosis
    Stephen J Nicholls
    University of Adelaide, Discipline of Medicine, Adelaide, Australia
    Expert Opin Pharmacother 15:1119-25. 2014
    ..The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more effective strategies to reduce cardiovascular risk...
  13. doi request reprint Intravascular imaging of vulnerable coronary plaque: current and future concepts
    Rishi Puri
    Cardiovascular Research Centre, Department of Medicine, University of Adelaide, North Terrace, SA, Australia
    Nat Rev Cardiol 8:131-9. 2011
    ..However, natural-history studies to validate the use of these novel imaging tools for enhanced risk prediction are needed before these strategies can be incorporated into mainstream clinical practice...
  14. doi request reprint Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study
    Rishi Puri
    Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia
    Eur Heart J 33:495-504. 2012
    ....